Director, Earle. A. Chiles Research Institute, Providence Cancer Center, Portland, Oregon
Oncology
Dr. Walter J. Urba, MD
|
|
Give Review
Walter Urba practices Oncology. He went to University of Miami Miller School of Medicine. University of Miami Miller School of Medicine is ranked 45/0 in Research/PrimaryCare. He received 5 awards: "America's Top Doctors", "America's Top Doctors for Cancer", "Portland Monthly Magazine", "Redbook Magazine: Top Breast Cancer Doctors" and "Top MD". Walter Urba is also a published physician. He has 53 publication published. The most recent publication is: Multispectral imaging of formalin-fixed tissue predicts ability to generate tumor-infiltrating lymphocytes from melanoma. He is registered with Medicare and accepts Medicare payments.
Publications
- Clinical deployment of antibodies for treatment of Melanoma.
- At the Bench: Adoptive cell therapy for Melanoma.
- OX40 Is a Potent Immune-Stimulating Target in Late-Stage Cancer Patients.
- The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma.
- Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced Melanoma.
- Melanoma: more answers, more questions.
- Radiation and immunotherapy: Renewed allies in the war on Cancer.
- Phase 1 study of stereotactic body radiotherapy and interleukin-2--tumor and immunological responses.
- Tumor-Derived Autophagosome Vaccine: Mechanism of Cross-Presentation and Therapeutic Efficacy.
- Multiple vaccinations: friend or foe.
- Redirecting T Cells.
- Signaling through OX40 enhances antitumor immunity.
- Improved survival with ipilimumab in patients with metastatic Melanoma.
- Safety and efficacy of PF-3512676 for the treatment of stage IV Renal cell carcinoma: an open-label, multicenter phase I/II study.
- Cross-presentation of tumor associated antigens through tumor-derived autophagosomes.
- Characterization of the class I-restricted gp100 Melanoma peptide-stimulated primary immune response in tumor-free vaccine-draining lymph nodes and peripheral blood.
- Phase I/II study of ipilimumab for patients with metastatic Melanoma.
- Treatment of biochemical recurrence of prostate Cancer with granulocyte-macrophage colony-stimulating factor secreting, allogeneic, cellular immunotherapy.
- Efficient cross-presentation depends on autophagy in tumor cells.
- Phenotype and functional characterization of long-term gp100-specific memory CD8+ T cells in Disease-free melanoma patients before and after boosting immunization.
- Combination chemotherapy and ALVAC-CEA/B7.1 vaccine in patients with metastatic colorectal Cancer.
- Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced Melanoma.
- Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of Melanoma and other malignancies.
- Phase I/II trial of outpatient PEG-interferon with interleukin-2 in advanced Renal cell carcinoma: a cytokine working group study.
- Bovine apolipoprotein B-100 is a dominant immunogen in therapeutic cell populations cultured in fetal calf serum in mice and humans.
- Induction of circulating tumor-reactive CD8+ T cells after vaccination of Melanoma patients with the gp100 209-2M peptide.
- Granulocyte macrophage colony-stimulating factor--secreting allogeneic cellular immunotherapy for hormone-refractory prostate Cancer.
- Polychromatic flow cytometry: a rapid method for the reduction and analysis of complex multiparameter data.
- Anti-OX40 (CD134) administration to nonhuman primates: immunostimulatory effects and toxicokinetic study.
- Efficacy of GM-CSF-producing tumor vaccine after docetaxel chemotherapy in mice bearing established Lewis Lung carcinoma.
- Interleukin-7-dependent expansion and persistence of Melanoma-specific T cells in lymphodepleted mice lead to tumor regression and editing.
- Immunotherapy for Melanoma: the good, the bad, and the future.
- Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic Renal cell carcinoma.
- Undefined-antigen vaccines.
- Reduced L-selectin (CD62LLow) expression identifies tumor-specific type 1 T cells from lymph nodes draining an autologous tumor cell vaccine.
- gp100(209-2M) peptide immunization of human lymphocyte antigen-A2+ stage I-III Melanoma patients induces significant increase in antigen-specific effector and long-ter...
- Immunological monitoring of patients with Melanoma after peptide vaccination using soluble peptide/HLA-A2 dimer complexes.
- Adjuvant high-dose bolus interleukin-2 for patients with high-risk Renal cell carcinoma: a cytokine working group randomized trial.
- Vaccination of women with metastatic breast Cancer, using a costimulatory gene (CD80)-modified, HLA-A2-matched, allogeneic, breast Cancer cell line: clinical and immun...
- Adjuvant immunization of HLA-A2-positive Melanoma patients with a modified gp100 peptide induces peptide-specific CD8+ T-cell responses.
- Identification of tumor-specific antibodies in patients with breast Cancer vaccinated with gene-modified allogeneic tumor cells.
- Immune effects of escalating doses of granulocyte-macrophage colony-stimulating factor added to a fixed, low-dose, inpatient interleukin-2 regimen: a randomized phase ...
- Regression of a mammary adenocarcinoma in STAT6-/- mice is dependent on the presence of STAT6-reactive T cells.
- TNF plays an essential role in tumor regression after adoptive transfer of perforin/IFN-gamma double knockout effector T cells.
- Allogeneic breast Cancer cell vaccines.
- CD28, TNF receptor, and IL-12 are critical for CD4-independent cross-priming of therapeutic antitumor CD8+ T cells.
- Development of antitumor immune responses in reconstituted lymphopenic hosts.
- Adoptive cellular therapy with tumor vaccine draining lymph node lymphocytes after vaccination with HLA-B7/beta2-microglobulin gene-modified autologous tumor cells.
- Are all hypotheses generated before data analysis prospective?
- Multispectral imaging of formalin-fixed tissue predicts ability to generate tumor-infiltrating lymphocytes from Melanoma.
- Durable responses and reversible toxicity of high-dose interleukin-2 treatment of melanoma and renal Cancer in a Community Hospital Biotherapy Program.
- A phase II study of bevacizumab and high-dose interleukin-2 in patients with metastatic Renal cell carcinoma: a Cytokine Working Group (CWG) study.
Schools
Univ Of Miami Sch Of Med
Morristown Meml Hospital
Med Br Nci
Procedures Preformed
- HPC Transplantation (Stem Cell Transplant)
Conditions Treated
- AdRenal Gland Cancer
- Anemia
- Breast Cancer
- Colorectal Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- America's Top Doctors
- America's Top Doctors for Cancer
- Portland Monthly Magazine
- Redbook Magazine: Top Breast Cancer Doctors
- Top MD
Education
-
National Institutes of Health Clinical Center -
University of Miami Miller School of Medicine
Hospital
-
Providence Portland Medical Center
Drug Facts
| NPI NUMBER | 1548253602 | |
| NPPES Provider LastName | URBA | |
| NPPES Provider FirstName | WALTER | |
| NPPES Provider ZIPCode | 97213 | |
| NPPES Provider State | OR | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 22.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1548253602 |
| Last Name Of The Provider | URBA |
| First Name Of The Provider | WALTER |
| View All |
Similar Doctors
|
Dr. Devon J. Webster, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Bruce W. Dana, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Brendan D. Curti, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Regan M. Duffy, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Lucy R. Langer, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Tibor J. Kovacsovics, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Aclan Dogan, MD
This Doctor is OpenDoctor Recommended.
|